AptarGroup, Inc. provides a range of packaging, dispensing, and sealing solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active packaging products. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. The company sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. AptarGroup, Inc. has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. The company was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
IPO Year:
Exchange: NYSE
Website: aptar.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2025 | $200.00 | Outperform | Raymond James |
| 1/6/2025 | $173.00 | Buy → Neutral | BofA Securities |
| 10/14/2024 | $155.00 → $215.00 | Hold → Buy | Jefferies |
| 4/29/2024 | Mkt Perform → Outperform | William Blair | |
| 1/3/2024 | $125.00 → $150.00 | Neutral → Outperform | Robert W. Baird |
| 1/20/2022 | $150.00 → $126.00 | Equal-Weight | Morgan Stanley |
| 12/22/2021 | $162.00 → $156.00 | Overweight | Wells Fargo |
| 12/20/2021 | $148.00 → $145.00 | Buy | Deutsche Bank |
| 11/1/2021 | $158.00 → $148.00 | Buy | Deutsche Bank |
| 9/13/2021 | $150.00 → $135.00 | Neutral | Baird |
11-K - APTARGROUP, INC. (0000896622) (Filer)
SD - APTARGROUP, INC. (0000896622) (Filer)
S-8 - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
10-Q - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
DEFA14A - APTARGROUP, INC. (0000896622) (Filer)
DEFA14A - APTARGROUP, INC. (0000896622) (Filer)
DEF 14A - APTARGROUP, INC. (0000896622) (Filer)
10-K - APTARGROUP, INC. (0000896622) (Filer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905451175/en/Sarah Glickman Joins Aptar's Board of Directors (Photo: Aptar) "We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah's extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005172/en/Julie Xing Joins Aptar's Board of Directors (Photo: Aptar) With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie's leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple g
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Matt Trerotola has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005805/en/Matt Trerotola Joins Aptar's Board of Directors (Photo: Aptar) Matt has served as the President and Chief Executive Officer for Enovis Corporation (formerly Colfax), an innovation-driven medical technology company, since 2015. As a highly accomplished leader with over 30 years of experience, he has a distinct focus on accelerating organic growth as well as s
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announced today that Candace Matthews has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005808/en/Candace Matthews Joins Aptar Board of Directors Candace is a highly accomplished business leader with over 30 years of experience developing and marketing products for the healthcare, cosmetics, food and beverage industries. Candace currently serves as the Chief Reputation Officer for Amway, overseeing the company's global reputation strategy and brand, along with its
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it will present at two upcoming investor conferences: The William Blair 45th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 3, 2025. Stephan Tanda, President and CEO, and Vanessa Kanu, Executive Vice President and CFO, will present at 9:40 a.m. Eastern Time. The Jefferies Global Healthcare Conference on Wednesday, June 4, 2025. Stephan Tanda, President and CEO, and Vanessa Kanu, Executive Vice President and CFO, will present at 2:00 p.m. Eastern Time. A live audio webcast and presentations materials from these events will be
Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 27, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark Invest's Cathie Wood recently pointed to breakthrough research from Mass General Brigham—where AI models identified cancer survival outcomes using facial photographs—as evidence that healthcare may become AI's "most profound application." As adoption moves from theory to practice, several tech and biotech players are already making real-world strides. Recent developments have come from Avant Technologies, Inc. (OTCQB:AVAI), Butterfly N
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501642213/en/Aptar Reports First Quarter 2025 Results First Quarter 2025 Highlights (compared to the prior year quarter) Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 mill
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is May 22, 2025, to stockholders of record as of May 1, 2025. As previously announced, Aptar will hold a conference call on Friday, May 2, 2025 at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. About Aptar
SmartTrack™ aims to reduce the need for clinical studies in generic drug product approvals AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of a clinical study to validate its proprietary SmartTrack™ platform. The platform was developed by Aptar's drug services company, Nanopharm. If validated, SmartTrack™ aims to reduce the need for clinical studies in generic drug product approvals by proving it can accurately predict clinical outcomes – removing a major barrier for pharma companies and regulators and paving the way for wider patient access to medications. This validation would estab
Places in top 1% of EcoVadis' rankings for all industries AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has achieved the Platinum level rating in recognition of its sustainability efforts from EcoVadis for the fifth consecutive year. The Platinum rating places Aptar among the top 1% of the more than 150,000 companies rated by EcoVadis across all industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250415248822/en/Aptar Receives Platinum Rating from EcoVadis for the Fifth Consecutive Year "Aptar is honored to once again achieve the EcoVadis Platinum
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has been named one of Barron's 100 Most Sustainable U.S. Companies for the seventh consecutive year and is ranked number 26 out of the top 100 companies for 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327061242/en/Graphic: Aptar Named One of Barron's 100 Most Sustainable U.S. Companies for the Seventh Consecutive Year. Used with permission. ©2025 Dow Jones & Company, Inc. "Being recognized as one of Barron's most sustainable companies for seven consecutive years is a true honor and a reflection of
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has been recognized for its leadership on climate change topics by the global environmental non-profit CDP, securing a place on its prestigious "A List." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320115749/en/Graphic: Aptar Recognized with Prestigious ‘A' Score on the CDP Climate Change Assessment Aptar was recognized for its actions to cut emissions, mitigate climate risks and further the low-carbon economy, based on the data reported by the Company through CDP's 2024 corporate questionnaire. In 2024,
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong fourth quarter results due to solid operational performance driven by top and bottom line improvements. Results were driven by sales growth in pharma solutions, increased demand for closures technologies and productivity gains across the company. Reported sales increased by 1% and core sales increased by 2% due to a negative currency effect. Aptar reported net income of $101 million for the quarter, a 62% increase from the prior year. In addition, the quarterly results benefited from a lower effective tax rate. This press release features multimedi
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that the Board declared a quarterly cash dividend of $0.45 per share. The payment date is February 26, 2025, to stockholders of record as of February 5, 2025. As previously announced, Aptar will hold a conference call on Friday, February 7, 2025 at 8:00 a.m. Central Time to discuss the Company's fourth quarter and year-end results for 2024. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501642213/en/Aptar Reports First Quarter 2025 Results First Quarter 2025 Highlights (compared to the prior year quarter) Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 mill
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is May 22, 2025, to stockholders of record as of May 1, 2025. As previously announced, Aptar will hold a conference call on Friday, May 2, 2025 at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. About Aptar
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong fourth quarter results due to solid operational performance driven by top and bottom line improvements. Results were driven by sales growth in pharma solutions, increased demand for closures technologies and productivity gains across the company. Reported sales increased by 1% and core sales increased by 2% due to a negative currency effect. Aptar reported net income of $101 million for the quarter, a 62% increase from the prior year. In addition, the quarterly results benefited from a lower effective tax rate. This press release features multimedi
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that the Board declared a quarterly cash dividend of $0.45 per share. The payment date is February 26, 2025, to stockholders of record as of February 5, 2025. As previously announced, Aptar will hold a conference call on Friday, February 7, 2025 at 8:00 a.m. Central Time to discuss the Company's fourth quarter and year-end results for 2024. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced the dates and times of quarterly conference calls for the year. Any updates to these dates or times will be communicated in subsequent press releases. Quarterly Conference Calls Press Release (1) Conference Call (2) 4th Quarter and Annual 2024 Results February 6, 2025 February 7, 2025, at 8:00 a.m. CT 1st Quarter 2025 Results May 1, 2025 May 2, 2025, at 8:00 a.m. CT 2nd Quarter 2025 Results July 31, 2025 August 1, 2025, at 8:00 a.m. CT 3rd Quarter 2025
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong third quarter results due to solid operational performance and margin improvement across the company. Results were driven by growth in proprietary drug delivery systems, as well as increased demand for closure technologies. Reported sales and core sales increased by 2%, as currency and acquisition effects did not impact the quarter. Aptar reported net income of $100 million for the quarter, a 19% increase from the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024363414/en/
The Board of Directors of AptarGroup, Inc. (NYSE:ATR) authorized the repurchase of up to $500 million of the Company's common stock. This new authorization replaces all previous authorizations. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. The Board also declared a quarterly cash dividend of $0.45 per share. The payment date is November 14, 2024, to stockholders of record as of October 24, 2024. Stephan Tanda, President and CEO, commented, "Aptar maintains a balanced approach to capital allocation, focused on returning capital to shareholders, as well as reinvesting in the business through capacity ex
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported solid second quarter results driven by continued growth of the company's proprietary drug delivery systems and margin improvement. Reported sales increased by 2% and core sales, excluding currency and acquisition effects, increased by 3%. Aptar reported net income of $90 million for the quarter, a 9% increase from the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725389689/en/Photo: Aptar "Strong sales growth in our Pharma business and broad-based margin expansion helped us achi
Following an increase of almost 8% a year ago AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share, an almost 10% increase from the previous dividend amount, bringing the new annualized dividend to $1.80 per share. The payment date is August 15, 2024, to stockholders of record as of July 25, 2024. Stephan B. Tanda, Aptar President and CEO, commented, "In light of our continued strong performance across all of our key financial metrics, as well as future growth opportunities, the Board of Directors approved an increase in the quarterly dividend. Over the
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong first quarter results driven by continued growth of the company's proprietary drug delivery systems, increased injectables sales and an improving picture for consumer dispensing technologies in North America. Reported sales increased by 6% and core sales, excluding currency and acquisition effects, increased by 5%. Aptar reported net income of $83 million for the quarter, a 52% increase over the prior year. Reported earnings per share increased 50% to $1.23 and adjusted earnings per share increased 31% to $1.26. This press release features multimed
Raymond James initiated coverage of AptarGroup with a rating of Outperform and set a new price target of $200.00
BofA Securities downgraded AptarGroup from Buy to Neutral and set a new price target of $173.00
Jefferies upgraded AptarGroup from Hold to Buy and set a new price target of $215.00 from $155.00 previously
William Blair upgraded AptarGroup from Mkt Perform to Outperform
Robert W. Baird upgraded AptarGroup from Neutral to Outperform and set a new price target of $150.00 from $125.00 previously
Morgan Stanley reiterated coverage of AptarGroup with a rating of Equal-Weight and set a new price target of $126.00 from $150.00 previously
Wells Fargo reiterated coverage of AptarGroup with a rating of Overweight and set a new price target of $156.00 from $162.00 previously
Deutsche Bank reiterated coverage of AptarGroup with a rating of Buy and set a new price target of $145.00 from $148.00 previously
Deutsche Bank reiterated coverage of AptarGroup with a rating of Buy and set a new price target of $148.00 from $158.00 previously
Baird reiterated coverage of AptarGroup with a rating of Neutral and set a new price target of $135.00 from $150.00 previously
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)